Home
Norwegian Multiple Sclerosis Competence Centre and Research Group
Obesity and interferon-beta treatment in MS

New article: Body mass index influence interferon-beta treatment response in multiple sclerosis.

Silje Kvistad and co-authors associated with Kristian Gerhard Jebsen Centre for MS Research and The Norwegian Multiple Sclerosis Competence Centre have recently published an article on obseity and interferon-beta treatment in MS in Journal of Neuroimmunology.

Obesity is a possible risk factor of multiple sclerosis (MS), but the association between obesity and MS disease activity has not been explored. In a cohort of 86 MS patients, 80% of overweight or obese patients (BMI≥25kg/m(2)) had MRI activity compared to 48% of the normal-weight patients (BMI<25kg/m(2)) (p=0.001) during interferon-beta treatment. NEDA-status (no evidence of disease activity) was defined as a composite that consisted of absence of any relapses, sustained disability-progression and MRI-activity. Among normal-weight patients 26% obtained NEDA-status compared to only 13% of patients with BMI >25 (p=0.05). This may indicate that BMI affects interferon-beta treatment response.

 

Referanse:

Kvistad SS, Myhr KM, Holmøy T, Šaltytė Benth J, Wergeland S, Beiske AG, Bjerve KS, Hovdal H, Lilleås F, Midgard R, Pedersen T, Bakke SJ, Michelsen AE, Aukrust P, Ueland T, Sagen JV, Torkildsen Ø. Body mass index influence interferon-beta treatment response in multiple sclerosis. J Neuroimmunol. 2015 Nov 15;288:92-7.